|
Transposition of Great Vessels
|
0.200 |
Biomarker
|
disease |
MGD |
Mice containing null mutations in Dvl2 present with 50% lethality in both inbred 129S6 and in a hybrid 129S6-NIH Black Swiss background because of severe cardiovascular outflow tract defects, including double outlet right ventricle, transposition of the great arteries and persistent truncus arteriosis.
|
12421720 |
2002 |
|
Transposition of the Great Arteries, Dextro-Looped 1
|
0.200 |
Biomarker
|
disease |
MGD |
Dishevelled 2 is essential for cardiac outflow tract development, somite segmentation and neural tube closure.
|
12421720 |
2002 |
|
Dextrotransposition of aorta
|
0.200 |
Biomarker
|
disease |
MGD |
Dishevelled 2 is essential for cardiac outflow tract development, somite segmentation and neural tube closure.
|
12421720 |
2002 |
|
Discordant ventriculoarterial connection
|
0.200 |
Biomarker
|
disease |
MGD |
Dishevelled 2 is essential for cardiac outflow tract development, somite segmentation and neural tube closure.
|
12421720 |
2002 |
|
Tumor Cell Invasion
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
Taken together, out study reveals an oncogenic role of ATDC that drives the growth and invasion of glioma by modulating the Wnt/Dvl2/β-catenin signaling pathway, suggesting a potential therapeutic target for treatment of glioma.
|
30929997 |
2019 |
|
Tumor Cell Invasion
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
Invasion and migration were detected by a transwell assay; cell cycle distribution and apoptosis were measured by flow cytometry analysis; Dvl2, GSK-3β, cyclin D1, and β-catenin expressions were detected by RT-PCR and Western blotting.
|
31173296 |
2019 |
|
Tumor Cell Invasion
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
Knockdown of Dvl-2 could inhibit proliferation and invasion of HB cell lines.
|
29528187 |
2018 |
|
Tumor Cell Invasion
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
Wound healing and transwell assays showed that knockdown of Dvl2 reduced cell migration and invasion in HepG2 cells.
|
28589433 |
2017 |
|
Tumor Cell Invasion
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
Wound-healing assay and transwell assay were used to examine the activities of migration and invasion in Dvl2-silenced ESCC cells.
|
27083564 |
2016 |
|
Tumor Cell Invasion
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
Here, we show that two activators of the canonical Wnt/beta-catenin transcription pathway, namely Dvl-2, the Axin 501-560 fragment binding glycogen synthase kinase -3beta (GSK-3beta), and the negative Wnt regulator wt-Axin did not alter cell invasion into type I collagen.
|
15507471 |
2005 |
|
Colorectal Carcinoma
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
Increased susceptibility to CRC was associated with the polymorphic variants rs11954856 (APC), rs222836 (DVL2), and rs9921222 (AXIN1).
|
31723073 |
2019 |
|
Colorectal Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Taken together, our data suggest that HMGA2 enhances the chemoresistance to 5-FU in CRC via activating the Dvl2/Wnt pathway.
|
29515783 |
2018 |
|
Colorectal Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
We recently identified that the KITENIN/ErbB4-Dvl2-c-Jun axis works as a novel unconventional downstream signal of epidermal growth factor (EGF) in colorectal cancer (CRC) tissues.
|
27648936 |
2017 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Dishevelled-2 (Dvl2) was associated with tumor cell proliferation and migration.
|
27083564 |
2016 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
In addition, Dvl2 depletion inhibited tumor formation after intracranial injection of glioblastoma cells in immunodeficient mice.
|
21990322 |
2011 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Taken together, our results suggested that GABARAPL1 as a tumor repressor inhibits Wnt signaling via mediating Dvl2 degradation through the autophagy pathway.
|
21691068 |
2011 |
|
Colorectal Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Our results implicate Dvl2 and mTOR in the progression of colorectal neoplasia and highlight their potential as therapeutic targets in colorectal cancer.
|
20663899 |
2010 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Dvl2 promotes intestinal length and neoplasia in the ApcMin mouse model for colorectal cancer.
|
20663899 |
2010 |
|
Malignant neoplasm of colon and/or rectum
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Genetic Polymorphisms in APC, DVL2, and AXIN1 Are Associated with Susceptibility, Advanced TNM Stage or Tumor Location in Colorectal Cancer.
|
31723073 |
2019 |
|
Malignant neoplasm of colon and/or rectum
|
0.030 |
Biomarker
|
disease |
BEFREE |
HMGA2 enhances 5-fluorouracil chemoresistance in colorectal cancer via the Dvl2/Wnt pathway.
|
29515783 |
2018 |
|
Neural Tube Defects
|
0.030 |
GeneticVariation
|
group |
BEFREE |
Recently, we have reported a possible role for rare variants of DVL2 as risk factors for NTDs.
|
23836490 |
2013 |
|
Neural Tube Defects
|
0.030 |
Biomarker
|
group |
BEFREE |
In this study, we analyzed the role of the human orthologs DVL2 and DVL3 in a cohort of 473 patients with neural tube defects.
|
22892949 |
2013 |
|
Neural Tube Defects
|
0.030 |
GeneticVariation
|
group |
BEFREE |
Our biochemical analyses revealed that among the five mutations, N356K and R45W show loss-of-function or reduced activities in inducing Dishevelled2 (DVL2) degradation and inhibiting jun-N-terminal kinase (JNK) phosphorylation, implicating mutated DACT1 as a risk factor for human NTDs.
|
22610794 |
2012 |
|
Malignant neoplasm of colon and/or rectum
|
0.030 |
Biomarker
|
disease |
BEFREE |
Our results implicate Dvl2 and mTOR in the progression of colorectal neoplasia and highlight their potential as therapeutic targets in colorectal cancer.
|
20663899 |
2010 |
|
Glioma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Taken together, out study reveals an oncogenic role of ATDC that drives the growth and invasion of glioma by modulating the Wnt/Dvl2/β-catenin signaling pathway, suggesting a potential therapeutic target for treatment of glioma.
|
30929997 |
2019 |